A Phase II Open Label Study to Evaluate the Safety and Efficacy of Prochymal (Ex-vivo Cultured Adult Human Mesenchymal Stem Cells) Infusion for the Salvage of Treatment-Refractory Acute GVHD Patients
Latest Information Update: 01 Feb 2022
At a glance
- Drugs Remestemcel-L (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- Sponsors Mesoblast; Osiris Therapeutics
- 07 Nov 2012 New trial record